2045-79-6

Usage

Uses

Used in Pharmaceutical Industry:
2-Methoxyphenethylamine is used as an HIV inhibitor for its potential to combat HIV and related viruses. It serves as a promising candidate in the development of antiviral medications due to its ability to inhibit the replication and progression of these viruses.

InChI:InChI=1/C9H13NO/c1-11-9-5-3-2-4-8(9)6-7-10/h2-5H,6-7,10H2,1H3/p+1

Upstream product

• 6342-77-4 2-methoxy-benzenepropanoic acid 
• 15241-32-4 1-methoxy-2-(2-nitrovinyl)benzene 
• 75-52-5 nitromethane 
• 135-02-4 ortho-anisaldehyde 
• 82204-36-2 (E)-2-(2-methoxyphenyl)acetaldehyde oxime 
• 36449-75-9 1-(2-bromoethyl)-2-methoxybenzene 
• 64-17-5 ethanol 
• 144-62-7 oxalic acid 
• 59734-18-8 3-(2-methoxy-phenyl)-propionic acid amide 

Downstream Products

• 69226-62-6 (2-methoxy-phenethyl)-urea 
• 104338-26-3 2-(2-methoxyphenyl)-N-methylethan-1-amine 
• 150871-44-6 N-<2-(2-methoxyphenyl)ethyl>acetamide 
• 111088-40-5 N-Propanoyl-2-(2-methoxyphenyl)ethanamine 
• 34162-11-3 α-Chlor-N-o-methoxyphenethylacetamid 
• 74944-03-9 (S)-2-[3-(2-methoxyphenethylamino)-2-hydroxy-1-propoxy]-3-cyanopyridine 
• 7555-94-4 4-methoxy-2,3-dihydro-1H-indole 
• 82173-91-9 N',N''-bis<2-(2-methoxyphenyl)ethyl>imidodisulfamide 

Relevant academic research and scientific papers

Direct Primary Amination of Alkylmetals with NH-Oxaziridine

A method for the primary electrophilic amination of primary, secondary, and tertiary organometallic substrates from a bench-stable NH-oxaziridine reagent is described. This facile and highly chemoselective transformation occurs at ambient temperature and without transition metal catalysts or purification by column chromatography to provide alkylamine products in a single step. Density functional theory (DFT) calculations revealed that, despite the basicity of alkylmetals, the direct NH-transfer pathway is favored over proton and O-transfer.

Synthesis and antioxidant characteristic of novel thiazolidinone derivatives

A series of novel thiazolidinone derivatives have been synthesized by solventless condensation of N-alkylamines with arylaldehydes at room temperature followed by a microwave assisted solventless addition of thioglycollic acid to the resultant imines. The synthesized compounds are characterized by 1H NMR, 13C NMR, MS and X-ray techniques and one of the synthesized thiazolidinones has been evaluated for its antioxidant property.

17a-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

Process for the preparation of (8As,12AS,13AS)-decahydroisoquino ((2,1-G) (1,6)-naphthyridin-8-one derivatives

The invention provides a process for preparing single enantiomers of compounds represented by the formula: STR1 and chiral acid addition salts thereof; wherein: X and Y are independently hydrogen; lower alkyl; lower alkoxy; or halo; or X and Y taken together is methylenedioxy or ethylene-1,2-dioxy; which includes reduction of a compound represented by the formula: STR2 to give a mixture of stereoisomers represented by the formula: STR3 wherein each wavy line independently represents a bond in either the α or β position; followed by dissolving the mixture of stereoisomers and a chiral resolving acid in a suitable solvent and allowing the solution to crystallize, giving a salt of the desired enantiomer.